59671-8 |
Estazolam |
MCnt |
Tiss |
Pt |
Qn |
Confirm |
|
ACTIVE |
Estazolam [Mass/mass] in Tissue by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/g |
5 ng/g |
|
|
|
|
|
DRUG/TOX |
|
59671-8 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Estazolam Tiss Cfm-mCnt |
|
|
|
N |
|
Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; Esilgan; Eurodin; GCMS; LC/MS/MS; Mass content; Nuctalon; Point in time; Prosom; QNT; Quan; Quant; Quantitative; Random; Tissue; Tissue, unspecified |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/g |
|
|
|
0 |
59672-6 |
Estazolam |
MCnc |
Urine |
Pt |
Qn |
Confirm |
|
ACTIVE |
Estazolam [Mass/volume] in Urine by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
5 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59672-6 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Estazolam Ur Cfm-mCnc |
|
|
|
N |
|
Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; Esilgan; Eurodin; GCMS; LC/MS/MS; Level; Mass concentration; Nuctalon; Point in time; Prosom; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.73 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59673-4 |
fentaNYL |
PrThr |
Urine |
Pt |
Ord |
Screen |
|
ACTIVE |
fentaNYL [Presence] in Urine by Screen method |
|
MIN |
DefinitionDescription |
|
|
|
1 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59673-4 |
|
Screen |
|
|
Both |
|
|
|
0 |
fentaNYL Ur Ql Scn |
|
|
|
N |
|
Actiq; Addiction; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Duragesic; Durogesic; Fenpat; fentanil; Illicit; Ordinal; Point in time; PotentialForAbuse; PR; QL; Qual; Qualitative; Random; Scn; Scr; Screen; Scrn; Sublimaze; UA; UR; Urn |
2.73 |
2.32 |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect new model for ordinal terms; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
59674-2 |
Flurazepam |
MCnc |
Bld |
Pt |
Qn |
|
|
ACTIVE |
Flurazepam [Mass/volume] in Blood |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
2 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59674-2 |
|
|
|
|
Both |
|
|
|
0 |
Flurazepam Bld-mCnc |
|
|
|
N |
|
Blood; Dalmane; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; WB; Whole blood |
2.73 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59675-9 |
Flurazepam |
MCnc |
Bld |
Pt |
Qn |
Confirm |
|
ACTIVE |
Flurazepam [Mass/volume] in Blood by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
2 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59675-9 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Flurazepam Bld Cfm-mCnc |
|
|
|
N |
|
Blood; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; Dalmane; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; WB; Whole blood |
2.73 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59676-7 |
Flurazepam |
MCnc |
Body fld |
Pt |
Qn |
|
|
ACTIVE |
Flurazepam [Mass/volume] in Body fluid |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
2 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59676-7 |
|
|
|
|
Both |
|
|
|
0 |
Flurazepam Fld-mCnc |
|
|
|
N |
|
B/F; BF; bod; Bodies; Body fluid; Body fluid, unsp; Dalmane; DRUG/TOXICOLOGY; Drugs; Fl; Fld; FLU; Fluid; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59677-5 |
Flurazepam |
MCnc |
Body fld |
Pt |
Qn |
Confirm |
|
ACTIVE |
Flurazepam [Mass/volume] in Body fluid by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
2 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59677-5 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Flurazepam Fld Cfm-mCnc |
|
|
|
N |
|
B/F; BF; bod; Bodies; Body fluid; Body fluid, unsp; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; Dalmane; DRUG/TOXICOLOGY; Drugs; Fl; Fld; FLU; Fluid; GCMS; LC/MS/MS; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.73 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59678-3 |
Flurazepam |
MCnt |
Tiss |
Pt |
Qn |
|
|
ACTIVE |
Flurazepam [Mass/mass] in Tissue |
|
MIN |
DefinitionDescription |
|
|
ng/g |
2 ng/g |
|
|
|
|
|
DRUG/TOX |
|
59678-3 |
|
|
|
|
Both |
|
|
|
0 |
Flurazepam Tiss-mCnt |
|
|
|
N |
|
Dalmane; DRUG/TOXICOLOGY; Drugs; Mass content; Point in time; QNT; Quan; Quant; Quantitative; Random; Tissue; Tissue, unspecified |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/g |
|
|
|
0 |
59679-1 |
Flurazepam |
MCnt |
Tiss |
Pt |
Qn |
Confirm |
|
ACTIVE |
Flurazepam [Mass/mass] in Tissue by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/g |
2 ng/g |
|
|
|
|
|
DRUG/TOX |
|
59679-1 |
|
Confirm |
|
|
Both |
|
|
|
0 |
Flurazepam Tiss Cfm-mCnt |
|
|
|
N |
|
Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; Dalmane; DRUG/TOXICOLOGY; Drugs; GCMS; LC/MS/MS; Mass content; Point in time; QNT; Quan; Quant; Quantitative; Random; Tissue; Tissue, unspecified |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/g |
|
|
|
0 |
5968-3 |
Plasminogen activator tissue type^20M post venistasis |
MCnc |
PPP |
Pt |
Qn |
Enzy |
|
DEPRECATED |
Deprecated Plasminogen activator tissue type [Units/volume] in Platelet poor plasma by Chromogenic method --20 minutes post venistasis |
|
DEL |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
COAG |
|
5968-3 |
|
Enzy |
|
|
|
|
|
|
0 |
Deprecated tPA 20M PPP-mCnc |
|
|
|
|
|
After; Blood plasminogen activator; COAGULATION; Hematology; Heme; Level; Mass concentration; Plas; Platelet poor plasma; PLG; PLGN; Point in time; Profibrinolysin; PST; QNT; Quan; Quant; Quantitative; Random; Tissue plasminogen activator; TPA; t-PA; Vascular plasminogen activator |
2.36 |
1.0d |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
59680-9 |
Gabapentin |
MCnc |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Gabapentin [Mass/volume] in Urine |
|
MIN |
DefinitionDescription |
|
|
ug/mL |
0.1 mcg/mL |
|
|
|
|
|
DRUG/TOX |
|
59680-9 |
|
|
|
|
Both |
|
|
|
0 |
Gabapentin Ur-mCnc |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; Horizant; Level; Mass concentration; Neurontin; Point in time; QNT; Quan; Quant; Quantitative; Random; UA; UR; Urn |
2.73 |
2.32 |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
59681-7 |
Gamma hydroxybutyrate |
PrThr |
Ser/Plas |
Pt |
Ord |
Screen |
|
ACTIVE |
Gamma hydroxybutyrate [Presence] in Serum or Plasma by Screen method |
|
MIN |
DefinitionDescription |
|
|
|
2 mcg/mL |
|
|
|
|
|
DRUG/TOX |
|
59681-7 |
|
Screen |
|
|
Both |
|
|
|
0 |
G-OH-Butyr SerPl Ql Scn |
|
|
|
N |
|
4-hydroxybutyrate; 4-hydroxybutyric acid; DRUG/TOXICOLOGY; Drugs; Gamma hydroxy butyrate; Gamma-hydroxybutyrate; Gamma-OH; GBH; Georgia home boy; GHb; G-OH-Butyr; Goop; Hydroxybutyric acid; Liquidx; Ordinal; Pl; Plasma; Plsm; Point in time; PR; QL; Qual; Qualitative; Random; Scn; Scr; Screen; Scrn; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
2.32 |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect new model for ordinal terms; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
59682-5 |
Hydroxyethylflurazepam |
MCnc |
Bld |
Pt |
Qn |
|
|
ACTIVE |
Hydroxyethylflurazepam [Mass/volume] in Blood |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
5 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59682-5 |
|
|
|
|
Both |
|
|
|
0 |
OH-Ethylfluraz Bld-mCnc |
|
|
|
N |
|
Blood; DRUG/TOXICOLOGY; Drugs; Flurazepam metabolite; Hydroxy ethylflurazepam; Level; Mass concentration; OH-Ethylfluraz; Point in time; QNT; Quan; Quant; Quantitative; Random; WB; Whole blood |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59683-3 |
Hydroxyethylflurazepam |
MCnc |
Bld |
Pt |
Qn |
Confirm |
|
ACTIVE |
Hydroxyethylflurazepam [Mass/volume] in Blood by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
5 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59683-3 |
|
Confirm |
|
|
Both |
|
|
|
0 |
OH-Ethylfluraz Bld Cfm-mCnc |
|
|
|
N |
|
Blood; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; Flurazepam metabolite; GCMS; Hydroxy ethylflurazepam; LC/MS/MS; Level; Mass concentration; OH-Ethylfluraz; Point in time; QNT; Quan; Quant; Quantitative; Random; WB; Whole blood |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59684-1 |
Hydroxyethylflurazepam |
MCnc |
Body fld |
Pt |
Qn |
|
|
ACTIVE |
Hydroxyethylflurazepam [Mass/volume] in Body fluid |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
5 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59684-1 |
|
|
|
|
Both |
|
|
|
0 |
OH-Ethylfluraz Fld-mCnc |
|
|
|
N |
|
B/F; BF; bod; Bodies; Body fluid; Body fluid, unsp; DRUG/TOXICOLOGY; Drugs; Fl; Fld; FLU; Fluid; Flurazepam metabolite; Hydroxy ethylflurazepam; Level; Mass concentration; OH-Ethylfluraz; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59685-8 |
Hydroxyethylflurazepam |
MCnc |
Body fld |
Pt |
Qn |
Confirm |
|
ACTIVE |
Hydroxyethylflurazepam [Mass/volume] in Body fluid by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
5 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59685-8 |
|
Confirm |
|
|
Both |
|
|
|
0 |
OH-Ethylfluraz Fld Cfm-mCnc |
|
|
|
N |
|
B/F; BF; bod; Bodies; Body fluid; Body fluid, unsp; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; Fl; Fld; FLU; Fluid; Flurazepam metabolite; GCMS; Hydroxy ethylflurazepam; LC/MS/MS; Level; Mass concentration; OH-Ethylfluraz; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59686-6 |
Hydroxyethylflurazepam |
MCnt |
Meconium |
Pt |
Qn |
Confirm |
|
ACTIVE |
Hydroxyethylflurazepam [Mass/mass] in Meconium by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/g |
5 ng/g |
|
|
|
|
|
DRUG/TOX |
|
59686-6 |
|
Confirm |
|
|
Both |
|
|
|
0 |
OH-Ethylfluraz Mec Cfm-mCnt |
|
|
|
N |
|
Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; Flurazepam metabolite; GCMS; Hydroxy ethylflurazepam; LC/MS/MS; Mass content; Mec; OH-Ethylfluraz; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/g |
|
|
|
0 |
59687-4 |
Hydroxyethylflurazepam |
MCnt |
Stool |
Pt |
Qn |
Confirm |
|
ACTIVE |
Hydroxyethylflurazepam [Mass/mass] in Stool by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/g |
5 ng/g |
|
|
|
|
|
DRUG/TOX |
|
59687-4 |
|
Confirm |
|
|
Both |
|
|
|
0 |
OH-Ethylfluraz Stl Cfm-mCnt |
|
|
|
N |
|
Bowel movement; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; Faecal; Faeces; Fecal; Feces; Flurazepam metabolite; GCMS; Hydroxy ethylflurazepam; LC/MS/MS; Mass content; OH-Ethylfluraz; Point in time; QNT; Quan; Quant; Quantitative; Random; Stl; Stool = Fecal |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/g |
|
|
|
0 |
59688-2 |
Hydroxyethylflurazepam |
MCnt |
Tiss |
Pt |
Qn |
|
|
ACTIVE |
Hydroxyethylflurazepam [Mass/mass] in Tissue |
|
MIN |
DefinitionDescription |
|
|
ng/g |
5 ng/g |
|
|
|
|
|
DRUG/TOX |
|
59688-2 |
|
|
|
|
Both |
|
|
|
0 |
OH-Ethylfluraz Tiss-mCnt |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; Flurazepam metabolite; Hydroxy ethylflurazepam; Mass content; OH-Ethylfluraz; Point in time; QNT; Quan; Quant; Quantitative; Random; Tissue; Tissue, unspecified |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/g |
|
|
|
0 |
59689-0 |
Hydroxyethylflurazepam |
MCnt |
Tiss |
Pt |
Qn |
Confirm |
|
ACTIVE |
Hydroxyethylflurazepam [Mass/mass] in Tissue by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/g |
5 ng/g |
|
|
|
|
|
DRUG/TOX |
|
59689-0 |
|
Confirm |
|
|
Both |
|
|
|
0 |
OH-Ethylfluraz Tiss Cfm-mCnt |
|
|
|
N |
|
Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; Flurazepam metabolite; GCMS; Hydroxy ethylflurazepam; LC/MS/MS; Mass content; OH-Ethylfluraz; Point in time; QNT; Quan; Quant; Quantitative; Random; Tissue; Tissue, unspecified |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/g |
|
|
|
0 |
5969-1 |
Plasmin-plasmin inhibitor complex |
MCnc |
PPP |
Pt |
Qn |
IA |
|
ACTIVE |
Plasmin-plasmin inhibitor complex [Mass/volume] in Platelet poor plasma by Immunoassay |
|
MAJ |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
COAG |
|
5969-1 |
|
IA |
|
|
Both |
|
|
|
0 |
PAP PPP IA-mCnc |
|
|
|
Y |
|
Alpha-2-anti plasmin; Alpha-2-antiplasmin; Alpha-2-AP; Antiplasmin; COAGULATION; Compx; EIA; ELFA; ELISA; Enzyme immunoassay; Hematology; Heme; IAA; Inhib; Inhibit; Level; Mass concentration; MEIA; PAP; Plas; Plasm Inhib; Plasmin-alpha-2-antiplasmin complex; Platelet poor plasma; Point in time; Primary fibrinolysis inhibitor; Primary plasmin inhibitor; QNT; Quan; Quant; Quantitative; Random; SUDS |
2.58 |
1.0d |
|
|
|
|
|
|
|
|
|
|
Renamed Method from "Imm" to "IA" for consistency across classes (approved by Laboratory LOINC Committee 2016 12). |
0 |
59690-8 |
Hydroxytriazolam |
MCnc |
Bld |
Pt |
Qn |
|
|
ACTIVE |
Hydroxytriazolam [Mass/volume] in Blood |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
5 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59690-8 |
|
|
|
|
Both |
|
|
|
0 |
OH-Triazolam Bld-mCnc |
|
|
|
N |
|
Addiction; Blood; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Hydroxy triazolam; Illicit; Level; Mass concentration; OH-Triazolam; OHTRZ; Point in time; PotentialForAbuse; QNT; Quan; Quant; Quantitative; Random; Triazolam metabolite; WB; Whole blood |
2.73 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59691-6 |
Hydroxytriazolam |
MCnc |
Bld |
Pt |
Qn |
Confirm |
|
ACTIVE |
Hydroxytriazolam [Mass/volume] in Blood by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
5 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59691-6 |
|
Confirm |
|
|
Both |
|
|
|
0 |
OH-Triazolam Bld Cfm-mCnc |
|
|
|
N |
|
Addiction; Blood; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; GCMS; Hydroxy triazolam; Illicit; LC/MS/MS; Level; Mass concentration; OH-Triazolam; OHTRZ; Point in time; PotentialForAbuse; QNT; Quan; Quant; Quantitative; Random; Triazolam metabolite; WB; Whole blood |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59692-4 |
Hydroxytriazolam |
MCnc |
Body fld |
Pt |
Qn |
|
|
ACTIVE |
Hydroxytriazolam [Mass/volume] in Body fluid |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
5 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59692-4 |
|
|
|
|
Both |
|
|
|
0 |
OH-Triazolam Fld-mCnc |
|
|
|
N |
|
Addiction; B/F; BF; bod; Bodies; Body fluid; Body fluid, unsp; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Fl; Fld; FLU; Fluid; Hydroxy triazolam; Illicit; Level; Mass concentration; OH-Triazolam; OHTRZ; Point in time; PotentialForAbuse; QNT; Quan; Quant; Quantitative; Random; Triazolam metabolite |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
59693-2 |
Hydroxytriazolam |
MCnc |
Body fld |
Pt |
Qn |
Confirm |
|
ACTIVE |
Hydroxytriazolam [Mass/volume] in Body fluid by Confirmatory method |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
5 ng/mL |
|
|
|
|
|
DRUG/TOX |
|
59693-2 |
|
Confirm |
|
|
Both |
|
|
|
0 |
OH-Triazolam Fld Cfm-mCnc |
|
|
|
N |
|
Addiction; B/F; BF; bod; Bodies; Body fluid; Body fluid, unsp; Cfm; CNFR; CNFRM; Conf; Confirmation; Confirmatory; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Fl; Fld; FLU; Fluid; GCMS; Hydroxy triazolam; Illicit; LC/MS/MS; Level; Mass concentration; OH-Triazolam; OHTRZ; Point in time; PotentialForAbuse; QNT; Quan; Quant; Quantitative; Random; Triazolam metabolite |
2.7 |
2.32 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |